New drug spesolimab under Real-World watch for rare skin disease

NCT ID NCT05670821

Completed Disease control Sponsor: Boehringer Ingelheim Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study monitored 52 Japanese patients with generalized pustular psoriasis (GPP) who received spesolimab for acute symptoms. Researchers tracked side effects and disease activity in everyday clinical settings, not a controlled lab environment. The goal was to see how well the drug works and how safe it is when used in real-world practice.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Spesolimab
What this could lead to: If successful, this study could confirm that spesolimab is safe and effective for controlling acute flares of generalized pustular psoriasis in everyday medical practice.
What could go wrong: This is a small, non-interventional observational study with no control group, so results may not prove cause and effect. Side effects are possible, and findings may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GENERALIZED PUSTULAR PSORIASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

generalized pustular psoriasis psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GENERALIZED PUSTULAR PSORIASIS

Contacts and locations

Locations

Nippon Boehringer Ingelheim Co., Ltd.

Tokyo, 1416017, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.